<!DOCTYPE html>



<html lang="en">



	<meta charset="UTF-8">

	<meta name="viewport" content="width=device-width, initial-scale=1.0">

	<style>


    .node {

        stroke: #fff;

        stroke-width: 2px;

    }

    

    .link {

        stroke: #777;

        stroke-width: 2px;

    }



</style>

<body>

<a href="https://riskrunners.com">Home</a><br>




<a href="#risk_factors">Jump to Risk Factors</a><br>



<a href="#industry">Jump to Industries</a><br>


<a href="#exposure">Jump to Exposures</a><br>


<a href="#event_code">Jump to Event Codes</a><br>


<a href="#wiki">Jump to Wiki Summary</a><br><br>


    <script src="https://d3js.org/d3.v3.min.js"></script>

    <script>


// set a width and height for our SVG

var width = 3000,


    height = 3000;

    
// setup links

var links =     [
{source: "START_HERE", target: "1: incorporated by reference", fill: "#339"},
{source: "1: incorporated by reference", target: "1: Annual Report ", fill: "#339"},
{source: "1: Annual Report ", target: "1: may affect future", fill: "#339"},
{source: "1: may affect future", target: "1: presented on page", fill: "#339"},
{source: "1: presented on page", target: "1: should carefully", fill: "#339"},
{source: "1: should carefully", target: "1: following risks", fill: "#339"},
{source: "1: following risks", target: "1: investment decision concerning", fill: "#339"},
{source: "1: incorporated by reference", target: "4: extremely competitive", fill: "#9ab973"},
{source: "4: extremely competitive", target: "4: competition could impair", fill: "#9ab973"},
{source: "4: competition could impair", target: "4: existing customers", fill: "#9ab973"},
{source: "4: existing customers", target: "4: attract new customers which", fill: "#9ab973"},
{source: "4: attract new customers which", target: "4: could harm", fill: "#9ab973"},
{source: "4: extremely competitive", target: "6: competitors", fill: "#1c352d"},
{source: "6: competitors", target: "7: competitors", fill: "#8f00ff"},
{source: "7: competitors", target: "7: health insurers managed health care", fill: "#8f00ff"},
{source: "7: health insurers managed health care", target: "7: retail chain", fill: "#8f00ff"},
{source: "7: retail chain", target: "7: independent", fill: "#8f00ff"},
{source: "7: independent", target: "7: greater financial marketing", fill: "#8f00ff"},
{source: "7: greater financial marketing", target: "7: resources than", fill: "#8f00ff"},
{source: "7: competitors", target: "12: lose relationships with one", fill: "#66b032"},
{source: "12: lose relationships with one", target: "12: key pharmaceutical manufacturers", fill: "#66b032"},
{source: "12: key pharmaceutical manufacturers", target: "12: by pharmaceutical manufacturers decline", fill: "#66b032"},
{source: "12: by pharmaceutical manufacturers decline", target: "12: adversely affected", fill: "#66b032"},
{source: "12: lose relationships with one", target: "13: relationships with numerous pharmaceutical manufacturers", fill: "#417dc1"},
{source: "13: relationships with numerous pharmaceutical manufacturers", target: "13: pay rebates administrative fees", fill: "#417dc1"},
{source: "13: pay rebates administrative fees", target: "13: discounts based on use", fill: "#417dc1"},
{source: "13: discounts based on use", target: "13: drugs by participants", fill: "#417dc1"},
{source: "13: relationships with numerous pharmaceutical manufacturers", target: "18: on brandname drugs", fill: "#4d5d53"},
{source: "18: on brandname drugs", target: "18: annual sales", fill: "#4d5d53"},
{source: "18: annual sales", target: "18: United States", fill: "#4d5d53"},
{source: "18: on brandname drugs", target: "21: generally", fill: "#f8b878"},
{source: "21: generally", target: "21: generic drugs dispensed by", fill: "#f8b878"},
{source: "21: generic drugs dispensed by", target: "21: mail service", fill: "#f8b878"},
{source: "21: mail service", target: "21: pharmacies than", fill: "#f8b878"},
{source: "21: pharmacies than", target: "21: earn on brandname drugs", fill: "#f8b878"},
{source: "21: generally", target: "24: liability", fill: "#1e90ff"},
{source: "24: liability", target: "24: covered by insurance", fill: "#1e90ff"},
{source: "24: liability", target: "28: Existing ", fill: "#00ff7f"},
{source: "28: Existing ", target: "28: government", fill: "#00ff7f"},
{source: "28: government", target: "28: legislative", fill: "#00ff7f"},
{source: "28: legislative", target: "28: regulatory", fill: "#00ff7f"},
{source: "28: regulatory", target: "28: adversely", fill: "#00ff7f"},
{source: "28: Existing ", target: "29: participant", fill: "#d6cadd"},
{source: "29: participant", target: "29: in the PBM ", fill: "#d6cadd"},
{source: "29: in the PBM ", target: "29: industries", fill: "#d6cadd"},
{source: "29: industries", target: "29: operations", fill: "#d6cadd"},
{source: "29: operations", target: "29: evolving federal", fill: "#d6cadd"},
{source: "29: evolving federal", target: "29: regulations", fill: "#d6cadd"},
{source: "29: regulations", target: "29: enforcement by federal", fill: "#d6cadd"},
{source: "29: enforcement by federal", target: "29: governmental agencies", fill: "#d6cadd"},
{source: "29: participant", target: "31: Uncertainty ", fill: "#0093af"},
{source: "31: Uncertainty ", target: "31: implementation", fill: "#0093af"},
{source: "31: implementation", target: "31: Medicare Part D ", fill: "#0093af"},
{source: "31: Medicare Part D ", target: "31: adversely impact", fill: "#0093af"},
{source: "31: Uncertainty ", target: "43: Congress ", fill: "#ff4500"},
{source: "43: Congress ", target: "43: periodically", fill: "#ff4500"},
{source: "43: periodically", target: "43: health care system", fill: "#ff4500"},
{source: "43: Congress ", target: "START_HERE", fill: "#ff4500"}]; 
    // create empty nodes array
    var nodes = {};
	var colorFill = [];
	
    // compute nodes from links data
    links.forEach(function(link) {
        link.source = nodes[link.source] ||
            (nodes[link.source] = {name: link.source});
        link.target = nodes[link.target] ||
            (nodes[link.target] = {name: link.target});
		colorFill.push({name: link.source.name, fill: link.fill });
		colorFill.push({name: link.target.name, fill: link.fill });
    });
	
	console.log(colorFill);


    // add a SVG to the body for our viz
    var svg=d3.select('body').append('svg')
        .attr("viewBox", "0 0 " + width + " " + height );

    // use the force
    var force = d3.layout.force()
		.charge(-5000)
		.gravity(0.3)
        .size([width, height])
        .nodes(d3.values(nodes))
        .links(links)
        .on("tick", tick)
        .linkDistance(200)
        .start();

    // add links
    var link = svg.selectAll('.link')
        .data(links)
        .enter().append('line')
        .attr('class', 'link'); 

    // add nodes
    var node = svg.selectAll('.node')
        .data(force.nodes())
        .enter().append('circle')
        .attr('class', 'node')
        .attr('r', width * 0.0035)
		.style("fill", function(d) {
									for (var i = 0; i < colorFill.length; i++) {
										//console.log(d.name);
										if(colorFill[i].name == d.name){
											console.log(colorFill[i].fill);
											return colorFill[i].fill;
										}
									} return "#555";
									
									});
	var label = svg.selectAll(null)
		.data(force.nodes())
		.enter()
		.append("text")
		.text(function (d) { return d.name; })
		.style("text-anchor", "middle")
		.style("fill", "#555")
		.style("font-family", "Arial")
		.style("font-size", 34);


    // what to do 
    function tick(e) {
        
        node.attr('cx', function(d) { return d.x = Math.max(6, Math.min(width - 6, d.x)); })
            .attr('cy', function(d) { return d.y = Math.max(6, Math.min(height - 6, d.y)); })
            .call(force.drag);
            
        link.attr('x1', function(d) { return d.source.x; })
            .attr('y1', function(d) { return d.source.y; })
            .attr('x2', function(d) { return d.target.x; })
            .attr('y2', function(d) { return d.target.y; });
		
		label.attr("x", function(d){ return d.x; })
             .attr("y", function (d) {return d.y - 10; });
        
    }
    
</script><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='industry'>Industries</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Independent Power Producers and Energy Traders</td>
    </tr>
    <tr>
      <td>Automobile Manufacturers</td>
    </tr>
    <tr>
      <td>Motorcycle Manufacturers</td>
    </tr>
    <tr>
      <td>Health Care Facilities</td>
    </tr>
    <tr>
      <td>Health Care Supplies</td>
    </tr>
    <tr>
      <td>Health Care</td>
    </tr>
    <tr>
      <td>Health Care Equipment and Services</td>
    </tr>
    <tr>
      <td>Managed Health Care</td>
    </tr>
    <tr>
      <td>Health Care Distribution and Services</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='exposure'>Exposures</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Express intent</td>
    </tr>
    <tr>
      <td>Regime</td>
    </tr>
    <tr>
      <td>Military</td>
    </tr>
    <tr>
      <td>Judicial</td>
    </tr>
    <tr>
      <td>Cooperate</td>
    </tr>
    <tr>
      <td>Leadership</td>
    </tr>
    <tr>
      <td>Material Aid</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='event_code'>Event Codes</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Sports contest</td>
    </tr>
    <tr>
      <td>Demand</td>
    </tr>
    <tr>
      <td>Host meeting</td>
    </tr>
    <tr>
      <td>Vote</td>
    </tr>
    <tr>
      <td>Solicit support</td>
    </tr>
    <tr>
      <td>Sanction</td>
    </tr>
    <tr>
      <td>Pessimistic comment</td>
    </tr>
    <tr>
      <td>Yield to order</td>
    </tr>
    <tr>
      <td>Release or return</td>
    </tr>
    <tr>
      <td>Consult</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='wiki'>Wiki</th>
      <th>Wiki Summary</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/United_States_Pharmacopeia">United States Pharmacopeia</a></td>
      <td>The United States Pharmacopeia (USP) is a pharmacopeia (compendium of drug information) for the United States published annually by the United States Pharmacopeial Convention (usually also called the USP), a nonprofit organization that owns the trademark and also owns the copyright on the pharmacopeia itself. The USP is published in a combined volume with the National Formulary (a formulary) as the USP-NF. If a drug ingredient or drug product has an applicable USP quality standard (in the form of a USP-NF monograph), it must conform in order to use the designation "USP" or "NF".</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/The_Second_Annual_Report">The Second Annual Report</a></td>
      <td>The Second Annual Report is the debut album by English industrial music group Throbbing Gristle, released in November 1977 through Industrial Records. It is a combination of live and studio recordings made from October 1976 to September 1977.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Comprehensive_annual_financial_report">Comprehensive annual financial report</a></td>
      <td>An Annual Comprehensive Financial Report, formally called Comprehensive Annual Financial Report (CAFR)) is a set of U.S. government financial statements comprising the financial report of a state, municipal or other governmental entity that complies with the accounting requirements promulgated by the Governmental Accounting Standards Board (GASB).  GASB provides standards for the content of a Comprehensive Annual Financial Report in its annually updated publication Codification of Governmental Accounting and Financial Reporting Standards.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/World_Happiness_Report">World Happiness Report</a></td>
      <td>The World Happiness Report is a publication of the United Nations Sustainable Development Solutions Network. It contains articles and rankings of national happiness, based on respondent ratings of their own lives, which the report also correlates with various (quality of) life factors.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/The_First_Annual_Report">The First Annual Report</a></td>
      <td>The First Annual Report is a bootleg album of music recorded by industrial music pioneers Throbbing Gristle in 1975. The recording originally went unreleased, and the band instead decided to release The Second Annual Report in 1977.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Competition_law">Competition law</a></td>
      <td>Competition law is the field of law that promotes or seeks to maintain market competition by regulating anti-competitive conduct by companies. Competition law is implemented through public and private enforcement.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Customer_relationship_management">Customer relationship management</a></td>
      <td>Customer relationship management (CRM) is a process in which a business or other organization administers its interactions with customers, typically using data analysis to study large amounts of information.CRM systems compile data from a range of different communication channels, including a company's website, telephone, email, live chat, marketing materials and more recently, social media. They allow businesses to learn more about their target audiences and how to best cater for their needs, thus retaining customers and driving sales growth.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Customer">Customer</a></td>
      <td>In sales, commerce, and economics, a customer (sometimes known as a client, buyer, or purchaser) is the recipient of a good, service, product or an idea - obtained from a seller, vendor, or supplier via a financial transaction or exchange for money or some  other valuable consideration.\n\n\n== Etymology and terminology ==\nEarly societies relied on a gift economy based on favours.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Public_Investment_Fund">Public Investment Fund</a></td>
      <td>The Public Investment Fund (PIF; Arabic: صندوق الإستثمارات العامة) is the sovereign wealth fund of Saudi Arabia. It is among the largest sovereign wealth funds in the world with total estimated assets of $600 billion (£490 billion).</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Competition">Competition</a></td>
      <td>Competition is a rivalry where two or more parties strive for a common goal which cannot be shared: where one's gain is the other's loss (an example of which is a zero-sum game). Competition can arise between entities such as organisms, individuals, economic and social groups, etc.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Competitor_backlinking">Competitor backlinking</a></td>
      <td>Competitor backlinking is a search engine optimization strategy that involves analyzing the backlinks of competing websites within a vertical search. The outcome of this activity is designed to increase organic search engine rankings and to gain an understanding of the link building strategies used by business competitors.By analyzing the backlinks to competitor websites, it is possible to gain a benchmark on the number of links and the quality of links that is required for high search engine rankings.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Competitor_Group">Competitor Group</a></td>
      <td>Competitor Group, Inc. (CGI) is a privately held, for-profit, sports marketing and management company based in Mira Mesa, San Diego, California.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Round-robin_tournament">Round-robin tournament</a></td>
      <td>A round-robin tournament (or all-play-all tournament) is a competition in which each contestant meets every other participant, usually in turn. A round-robin contrasts with an elimination tournament, in which participants are eliminated after a certain number of losses.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Health_insurance">Health insurance</a></td>
      <td>Health insurance or medical insurance (also known as medical aid in South Africa) is a type of insurance that covers the whole or a part of the risk of a person incurring medical expenses. As with other types of insurance is risk among many individuals.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/UnitedHealth_Group">UnitedHealth Group</a></td>
      <td>UnitedHealth Group Incorporated is an American multinational managed healthcare and insurance company based in Minnetonka, Minnesota. It offers health care products and insurance services.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Pharmaceutical_industry">Pharmaceutical industry</a></td>
      <td>The pharmaceutical industry discovers, develops, produces, and markets drugs or pharmaceutical drugs for use as medications to be administered to patients (or self-administered), with the aim to cure them, vaccinate them, or alleviate symptoms.  Pharmaceutical companies may deal in generic or brand medications and medical devices.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Medication">Medication</a></td>
      <td>Meditation is a practice in which an individual uses a technique – such as mindfulness, or focusing the mind on a particular object, thought, or activity – to train attention and awareness, and achieve a mentally clear and emotionally calm and stable state.Meditation  is practiced in numerous religious traditions. The earliest records of meditation (dhyana) are found in the Upanishads of Hindu philosophy, and meditation plays a salient role in the contemplative repertoire of Buddhism and Hinduism.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Pharmacy_benefit_management">Pharmacy benefit management</a></td>
      <td>In the United States, a pharmacy benefit manager (PBM) is a third-party administrator of prescription drug programs for commercial health plans, self-insured employer plans, Medicare Part D plans, the Federal Employees Health Benefits Program, and state government employee plans. According to the American Pharmacists Association, "PBMs are primarily responsible for developing and maintaining the formulary, contracting with pharmacies, negotiating discounts and rebates with drug manufacturers, and processing and paying prescription drug claims." PBMs operate inside of integrated healthcare systems (e.g., Kaiser Permanente or Veterans Health Administration), as part of retail pharmacies (e.g., CVS Pharmacy or Rite-Aid), and as part of insurance companies (e.g., UnitedHealth Group).As of 2016, PBMs managed pharmacy benefits for 266 million Americans.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/List_of_drugs:_Cf–Ch">List of drugs: Cf–Ch</a></td>
      <td>This multi-page article lists pharmaceutical drugs alphabetically by name. Many drugs have more than one name and, therefore, the same drug may be listed more than once.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Tylenol_(brand)">Tylenol (brand)</a></td>
      <td>Tylenol () is a brand of drugs advertised for reducing pain, reducing fever, and relieving the symptoms of allergies, cold, cough, headache, and influenza. The active ingredient of its original flagship product is paracetamol (known in the United States, Canada, and various other countries as acetaminophen), an analgesic and antipyretic.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Metamizole">Metamizole</a></td>
      <td>Metamizole, or dipyrone, is a painkiller, spasm reliever, and fever reliever that also has anti-inflammatory effects. It is most commonly given by mouth or by intravenous infusion.Although it is available over-the-counter in some countries, it is banned in others, due to its potential for adverse events, including agranulocytosis.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Aspirin/paracetamol/caffeine">Aspirin/paracetamol/caffeine</a></td>
      <td>Aspirin/paracetamol(acetaminophen)/caffeine is a combination drug for the treatment of pain, especially tension headache and migraine. It is sold in the US under the trade names Goody's Powder and Excedrin, although not all products sold under the Excedrin brand contain this combination.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Prescription_drug">Prescription drug</a></td>
      <td>A prescription drug (also prescription medication or prescription medicine) is a pharmaceutical drug that legally requires a medical prescription to be dispensed. In contrast, over-the-counter drugs can be obtained without a prescription.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Liability_insurance">Liability insurance</a></td>
      <td>Liability insurance (also called third-party insurance) is a part of the general insurance system of risk financing to protect the purchaser (the "insured") from the risks of liabilities imposed by lawsuits and similar claims and protects the insured if the purchaser is sued for claims that come within the coverage of the insurance policy.\nOriginally, individual companies that faced a common peril formed a group and created a self-help fund out of which to pay compensation should any member incur loss (in other words, a mutual insurance arrangement).</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Australian_Government">Australian Government</a></td>
      <td>The Australian Government, also known as the Commonwealth Government, is the national government of Australia, a federal parliamentary constitutional monarchy. Like other Westminster-style systems of government, the Australian Government is made up of three branches: the executive (the prime minister, the ministers, and government departments), the legislative (the Parliament of Australia), and the judicial.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Adverse_food_reaction">Adverse food reaction</a></td>
      <td>An adverse food reaction is an adverse response by the body to food or a specific type of food.The most common adverse reaction is a food allergy, which is an adverse immune response to either a specific type or a range of food proteins.\nHowever, other adverse responses to food are not allergies.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Adverse_party">Adverse party</a></td>
      <td>An adverse party is an opposing party in a lawsuit under an adversary system of law.  In general, an adverse party is a party against whom judgment is sought or "a party interested in sustaining a judgment or decree." For example, the adverse party for a defendant is the plaintiff.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Material_adverse_change">Material adverse change</a></td>
      <td>In the fields of mergers and acquisitions and corporate finance, a material adverse change (abbreviated MAC), material adverse event (MAE), or material adverse effect (also MAE) is a change in circumstances that significantly reduces the value of a company. A contract to acquire, invest in, or lend money to a company often contains a  term that allows the acquirer, investor, or lender to cancel the transaction if a material adverse change occurs.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Regulation_(European_Union)">Regulation (European Union)</a></td>
      <td>A regulation is a legal act of the European Union that becomes immediately enforceable as law in all member states simultaneously. Regulations can be distinguished from directives which, at least in principle, need to be transposed into national law.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Medicare_Part_D_coverage_gap">Medicare Part D coverage gap</a></td>
      <td>The Medicare Part D coverage gap (informally known as the Medicare doughnut hole) is a period of consumer payment for prescription medication costs which lies between the initial coverage limit and the catastrophic-coverage threshold, when the consumer is a member of a Medicare Part D prescription-drug program administered by the United States federal government. The gap is reached after shared insurer payment - consumer payment for all covered prescription drugs reaches a government-set amount, and is left only after the consumer has paid full, unshared costs of an additional amount for the same prescriptions.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Medicare_Prescription_Drug,_Improvement,_and_Modernization_Act">Medicare Prescription Drug, Improvement, and Modernization Act</a></td>
      <td>The Medicare Prescription Drug, Improvement, and Modernization Act, also called the Medicare Modernization Act or MMA, is a federal law of the United States, enacted in 2003. It produced the largest overhaul of Medicare in the public health program's 38-year history.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Out-of-pocket_expense">Out-of-pocket expense</a></td>
      <td>An out-of-pocket expense (or out-of-pocket cost, OOP) is the direct payment of money that may or may not be later reimbursed from a third-party source.\nFor example, when operating a vehicle, gasoline, parking fees and tolls are considered out-of-pocket expenses for a trip.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Health_system">Health system</a></td>
      <td>A health system, also known as health care system or healthcare system, is the organization of people, institutions, and resources that deliver health care services to meet the health needs of target populations.\nThere is a wide variety of health systems around the world, with as many histories and organizational structures as there are nations.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Health_care_in_the_United_States">Health care in the United States</a></td>
      <td>Health care in the United States is provided by many distinct organizations, made up of insurance companies, healthcare providers, hospital systems, and independent providers. Health care facilities are largely owned and operated by private sector businesses.</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='risk_factors'>Risk Factors</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>CAREMARK RX INC      Item 1A Risk Factors          In addition to the other information included and <font color="blue">incorporated by reference</font>     in this <font color="blue">Annual Report </font>on Form 10-K, including the listing of factors that     <font color="blue">may affect future</font> results <font color="blue">presented on page</font> i, “Forward-Looking Statements     and Factors That May Affect Future Results,” you <font color="blue">should carefully</font> consider     the <font color="blue">following risks</font> before making an <font color="blue">investment decision concerning</font> Caremark     Rx,  Inc</td>
    </tr>
    <tr>
      <td>You <font color="blue">should also</font> read and consider the other     information in this <font color="blue">Annual Report </font>on Form 10-K and the other <font color="blue">documents</font>     <font color="blue">incorporated by reference</font> in this <font color="blue">Annual Report </font>on Form 10-K See Part I,     Item 1, “Business—Address and Availability of Information” on page 1</td>
    </tr>
    <tr>
      <td>The PBM industry is <font color="blue">extremely <font color="blue">competitive</font></font> and <font color="blue"><font color="blue">competition</font> could impair</font> our     ability to maintain <font color="blue">existing customers</font> and <font color="blue">attract new</font> customers, which     <font color="blue">could harm</font> our business and financial results</td>
    </tr>
    <tr>
      <td>The PBM industry is <font color="blue">extremely <font color="blue">competitive</font></font></td>
    </tr>
    <tr>
      <td>Some of our <font color="blue">competitors</font> are     large, well-established and profitable companies</td>
    </tr>
    <tr>
      <td>These <font color="blue">competitors</font> include     several large health insurers, managed <font color="blue">health care</font> plans, <font color="blue">retail chain</font>     stores and <font color="blue">independent</font> PBMs that may possess greater financial, marketing     and other <font color="blue">resources than</font> we                                           17     ______________________________________________________________________       do</td>
    </tr>
    <tr>
      <td>Some of these <font color="blue">competitors</font> may offer services and pricing terms that we,     as an <font color="blue">independent</font> PBM company, may not be able to offer</td>
    </tr>
    <tr>
      <td>This <font color="blue">competition</font>     may make it more <font color="blue">difficult</font> to maintain <font color="blue">existing customers</font> and <font color="blue">attract new</font>     customers and may cause us to face the risk of <font color="blue">declining <font color="blue">reimbursement</font></font>     <font color="blue">levels without</font> achieving <font color="blue">corresponding reductions</font> in costs of revenues</td>
    </tr>
    <tr>
      <td>As a     result, we may not continue to remain <font color="blue">competitive</font>, and <font color="blue">competition</font> could     have an adverse effect on our business and financial results</td>
    </tr>
    <tr>
      <td>If we <font color="blue">lose relationships with one</font> or more <font color="blue"><font color="blue">key <font color="blue">pharmaceutical</font></font> <font color="blue">manufacturers</font></font>     or  if  the payments made <font color="blue">by <font color="blue">pharmaceutical</font> <font color="blue">manufacturers</font> decline</font>, our     business and financial results could be <font color="blue"><font color="blue">adversely</font> affected</font></td>
    </tr>
    <tr>
      <td>We have business <font color="blue">relationships with numerous <font color="blue">pharmaceutical</font> <font color="blue">manufacturers</font></font>     that pay rebates, <font color="blue">administrative fees</font> or other <font color="blue"><font color="blue">discounts</font> based on use</font> of     selected  <font color="blue">drugs by <font color="blue">participant</font>s</font> in the benefit plans we manage for our     customers</td>
    </tr>
    <tr>
      <td>We also have <font color="blue">contractual arrangements under which</font> we receive fees     <font color="blue">from <font color="blue">pharmaceutical</font> <font color="blue">manufacturers</font></font> for other programs and services that we     provide</td>
    </tr>
    <tr>
      <td>Our business and financial results could be <font color="blue"><font color="blue">adversely</font> affected</font> if:           •   we were to <font color="blue">lose relationships with one</font> or more <font color="blue">key <font color="blue">pharmaceutical</font></font>     <font color="blue">manufacturers</font>;           •   rebates or other <font color="blue">discounts</font> decline due to changes in <font color="blue">utilization</font> of     specified <font color="blue">pharmaceutical</font> products by health plan sponsors and other clients;           •   <font color="blue">legal restrictions</font> are <font color="blue">imposed on</font> the ability of <font color="blue">pharmaceutical</font>     <font color="blue">manufacturers</font> to <font color="blue">offer rebates</font>, <font color="blue">administrative fees</font> or other <font color="blue">discounts</font> or to     purchase our programs or services; or           •   <font color="blue">pharmaceutical</font> <font color="blue">manufacturers</font> choose not to <font color="blue">offer rebates</font>,     <font color="blue">administrative fees</font> or other <font color="blue">discounts</font> or to purchase our programs or     services</td>
    </tr>
    <tr>
      <td>The launch of generic <font color="blue">pharmaceutical</font>s into the <font color="blue">marketplace may impact</font> our     financial results</td>
    </tr>
    <tr>
      <td>Rebates <font color="blue">on drugs on <font color="blue">which patents</font></font> are expected to expire over the next     <font color="blue">several years currently contribute <font color="blue">significantly</font></font> to our <font color="blue">earned rebates</font></td>
    </tr>
    <tr>
      <td>During 2006 and 2007 patents are expected to expire on brand-name drugs     representing approximately dlra20 billion in <font color="blue">annual sales</font> in the <font color="blue">United States</font></td>
    </tr>
    <tr>
      <td>As  these  patents  expire,  the  <font color="blue">introduction</font> of <font color="blue">generic products may</font>     <font color="blue">substantially</font>  reduce the market share of the brand-name drugs and the     rebates <font color="blue">manufacturers</font> provide to us for their brand-name drugs that are     included on the <font color="blue">formularies</font> we manage</td>
    </tr>
    <tr>
      <td>We also may not be able to negotiate     rebates for new brand-name drugs comparable to those rebates we are earning     on brand-name drugs on <font color="blue">which patents</font> are expected to expire</td>
    </tr>
    <tr>
      <td>We <font color="blue">generally</font>     earn  higher  margins  on  <font color="blue">generic drugs dispensed by</font> our <font color="blue">mail service</font>     <font color="blue">pharmacies than</font> we earn on brand-name drugs</td>
    </tr>
    <tr>
      <td>However, <font color="blue">manufacturers</font> of     newly-introduced generic drugs sometimes benefit from an <font color="blue">exclusive marketing</font>     period, <font color="blue">generally</font> six months, during which we may be unable to earn these     <font color="blue">higher margins</font></td>
    </tr>
    <tr>
      <td>The typically <font color="blue">higher margins</font> we <font color="blue">earn on generic drugs</font> and     the  rebates we earn by adding newly-approved, brand-name drugs to our     <font color="blue">formularies</font> may not offset any decline in rebates for brand-name drugs on     <font color="blue">which patents</font> expire</td>
    </tr>
    <tr>
      <td>We may be subject to <font color="blue">liability</font> claims for damages and other expenses that     are not <font color="blue">covered by insurance</font></td>
    </tr>
    <tr>
      <td>A  <font color="blue">successful product</font> or professional <font color="blue">liability</font> claim in excess of our     insurance  coverage  <font color="blue">could harm</font> our <font color="blue">financial condition</font> and results of     <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>Various aspects of our business may subject us to <font color="blue">litigation</font> and     <font color="blue">liability</font> for damages, including the performance of PBM services, including     <font color="blue">formulary management</font> and <font color="blue">health improvement</font> and <font color="blue">clinical services</font>, and the     operation of our pharmacies and websites</td>
    </tr>
    <tr>
      <td>We believe that most of the claims described in Note 14, “Contingencies,” to     our <font color="blue">consolidated</font> financial statements included in Part II, Item 8 of this     <font color="blue">Annual Report </font>on Form 10-K are unlikely to be <font color="blue">covered by insurance</font></td>
    </tr>
    <tr>
      <td>18     ______________________________________________________________________       <font color="blue">Existing  </font>and  new  <font color="blue">government</font> <font color="blue">legislative</font> and <font color="blue">regulatory</font> action could     <font color="blue">adversely</font> affect our business and financial results</td>
    </tr>
    <tr>
      <td>As a <font color="blue">participant</font> in the healthcare and PBM <font color="blue">industries</font>, our <font color="blue">operations</font> are     subject to complex and <font color="blue">evolving federal</font> and state laws and <font color="blue">regulations</font> and     <font color="blue">enforcement by federal</font> and state <font color="blue">government</font>al agencies</td>
    </tr>
    <tr>
      <td>These laws and     <font color="blue">regulations</font> are described in detail at Part I, Item 1, “Business—Government     Regulation</td>
    </tr>
    <tr>
      <td>”         <font color="blue">Uncertainty </font>regarding the <font color="blue">implementation</font> and impact of <font color="blue">Medicare Part D </font>may     <font color="blue">adversely</font> impact our business and financial results</td>
    </tr>
    <tr>
      <td>The MMA created a new, voluntary <font color="blue"><font color="blue">prescription</font> drug</font> benefit for Medicare     <font color="blue">beneficiaries entitled</font> to Medicare <font color="blue">benefits under</font> Part A or enrolled in     <font color="blue">Medicare Part B The Medicare Drug Benefit </font><font color="blue">became effective on</font> January 1,     2006</td>
    </tr>
    <tr>
      <td>We <font color="blue">participate</font> in the <font color="blue">administration</font> of the Medicare Drug Benefit:     (i) through the provision of PBM services to our health plan clients and     other clients that have <font color="blue">qualified as</font> a <font color="blue">Medicare Part D </font><font color="blue"><font color="blue">prescription</font> drug</font>     plan, (ii) through the offering of <font color="blue">Medicare Part D </font><font color="blue">pharmacy benefits by</font> our     subsidiary, SilverScript Insurance Company, which has <font color="blue">been approved by</font> CMS     as a <font color="blue"><font color="blue">prescription</font> drug</font> plan under <font color="blue">Medicare Part D </font>in all regions of the     country,  and (iii) by assisting employer, union and other health plan     clients that qualify for the <font color="blue">retiree drug subsidy available under</font> Medicare     Part D <font color="blue">by collecting</font> and submitting eligibility and/or drug cost data to CMS     for  them  in order to obtain the subsidy</td>
    </tr>
    <tr>
      <td>Our <font color="blue">clients could decide</font> to     discontinue providing <font color="blue"><font color="blue">prescription</font> drug</font> benefits to their Medicare-eligible     members</td>
    </tr>
    <tr>
      <td>If this occurs, the <font color="blue">adverse effects</font> of the Part D <font color="blue">benefit may</font>     outweigh any <font color="blue">opportunities</font> for new business <font color="blue">generated by</font> the new benefit</td>
    </tr>
    <tr>
      <td>We     are not yet able to assess the impact that <font color="blue">Medicare Part D </font>will have on our     clients’ decisions to continue to offer a <font color="blue"><font color="blue">prescription</font> drug</font> benefit to their     Medicare-eligible members</td>
    </tr>
    <tr>
      <td>In addition, if the cost and <font color="blue">complexity</font> of the     recent  changes  exceed  our <font color="blue">expectations</font> or <font color="blue">prevent effective program</font>     <font color="blue">implementation</font>; if the <font color="blue">government</font> alters or <font color="blue">reduces funding</font> of Medicare     programs because of the higher-than-anticipated cost to taxpayers of the MMA     or for other reasons; if we fail to design and maintain programs that are     attractive  to  Medicare  <font color="blue">participant</font>s; or if we are not successful in     retaining enrollees, or <font color="blue">winning contract renewals</font> or <font color="blue">new contracts under</font> the     MMA’s <font color="blue">competitive</font> bidding process, our current Medicare business and our     ability to expand our Medicare <font color="blue">operations</font> could be <font color="blue">materially</font> and <font color="blue">adversely</font>     affected, and we may not be able to realize any return on our <font color="blue">investments</font> in     Medicare <font color="blue">initiatives</font></td>
    </tr>
    <tr>
      <td><font color="blue">Efforts  </font>to  reduce  <font color="blue">health care</font> costs and alter <font color="blue">health care</font> financing     practices could <font color="blue">adversely</font> affect our business</td>
    </tr>
    <tr>
      <td>During the past several years, the US <font color="blue">healthcare industry</font> has been subject     to an increase in <font color="blue">government</font>al regulation at both the federal and state     levels</td>
    </tr>
    <tr>
      <td>Efforts to control healthcare costs, including <font color="blue"><font color="blue">prescription</font> drug</font>     costs, are underway at the federal and state <font color="blue">government</font> levels</td>
    </tr>
    <tr>
      <td><font color="blue">Changing     </font>political,  economic  and <font color="blue">regulatory</font> influences may affect <font color="blue">health care</font>     financing and <font color="blue"><font color="blue">reimbursement</font> practices</font></td>
    </tr>
    <tr>
      <td>If the current <font color="blue">health care</font> financing     and  <font color="blue">reimbursement</font> system changes <font color="blue">significantly</font>, our business could be     <font color="blue">materially</font> <font color="blue"><font color="blue">adversely</font> affected</font></td>
    </tr>
    <tr>
      <td><font color="blue">Congress </font><font color="blue">periodically</font> considers proposals to     reform the US <font color="blue"><font color="blue">health care</font> system</font></td>
    </tr>
    <tr>
      <td>These <font color="blue">proposals may</font> increase <font color="blue">government</font>     <font color="blue">involvement</font> in <font color="blue">health care</font> and regulation of PBM services, or otherwise     change the way our clients do business</td>
    </tr>
    <tr>
      <td>Health plan <font color="blue">sponsors may react</font> to     these proposals and the <font color="blue">uncertainty surrounding them by reducing</font> or delaying     purchases of <font color="blue">cost control mechanisms</font> and related services that we provide</td>
    </tr>
    <tr>
      <td>We <font color="blue">cannot predict</font> what effect, if any, these <font color="blue">proposals may</font> have on our     business</td>
    </tr>
    <tr>
      <td>Other <font color="blue">legislative</font> or market-driven changes in the <font color="blue">health care</font>     system that we cannot anticipate could also <font color="blue">materially</font> <font color="blue">adversely</font> affect our     <font color="blue">consolidated</font> results of <font color="blue">operations</font>, <font color="blue">consolidated</font> financial position and/or     <font color="blue">consolidated</font> cash flow from <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>We are the subject of <font color="blue">various legal proceedings</font></td>
    </tr>
    <tr>
      <td>We are parties to <font color="blue">legal proceedings challenging certain</font> of their business     practices</td>
    </tr>
    <tr>
      <td>The material <font color="blue">legal proceedings affecting us</font> are described in</td>
    </tr>
  </tbody>
</table>